批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
| 审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2014/04/17 |
ORIG-1(原始申请) |
Approval |
Type 7 - Drug Already Marketed without Approved NDA |
STANDARD
|
|
|
>>>补充申请<<<
| 审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2023/04/12 |
SUPPL-30(补充) |
Approval |
Manufacturing (CMC)-New Strength |
N/A
|
|
|
| 2022/12/06 |
SUPPL-27(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2022/11/22 |
SUPPL-26(补充) |
Approval |
Labeling-Container/Carton Labels |
STANDARD
|
|
|
| 2022/09/14 |
SUPPL-25(补充) |
Approval |
Labeling-Container/Carton Labels |
STANDARD
|
|
|
| 2021/04/21 |
SUPPL-20(补充) |
Approval |
Manufacturing (CMC)-Manufacturing Process |
N/A
|
|
|
| 2021/03/26 |
SUPPL-11(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2021/03/15 |
SUPPL-17(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2020/04/15 |
SUPPL-13(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2020/02/21 |
SUPPL-14(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2019/05/14 |
SUPPL-9(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2016/12/17 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2016/03/21 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/05/07 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2014/09/18 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
>>>活性成分:VASOPRESSIN; 剂型/给药途径:SOLUTION;INTRAVENOUS; 规格:20UNITS/ML (20UNITS/ML); 治疗等效代码:AP<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 204485 |
001 |
NDA |
VASOSTRICT |
VASOPRESSIN |
SOLUTION;INTRAVENOUS |
20UNITS/ML (20UNITS/ML) |
Prescription |
Yes |
Yes |
AP |
2014/04/17
|
PH HEALTH |
| 211538 |
001 |
ANDA |
VASOPRESSIN |
VASOPRESSIN |
SOLUTION;INTRAVENOUS |
20UNITS/ML (20UNITS/ML) |
Prescription |
No |
No |
AP |
2021/12/15
|
EAGLE PHARMS |
| 211857 |
001 |
ANDA |
VASOPRESSIN |
VASOPRESSIN |
SOLUTION;INTRAVENOUS |
20UNITS/ML (20UNITS/ML) |
Prescription |
No |
No |
AP |
2022/07/18
|
AMPHASTAR PHARMS INC |
| 212944 |
001 |
ANDA |
VASOPRESSIN |
VASOPRESSIN |
SOLUTION;INTRAVENOUS |
20UNITS/ML (20UNITS/ML) |
Prescription |
No |
No |
AP |
2022/08/05
|
AMNEAL |
| 214314 |
001 |
ANDA |
VASOPRESSIN |
VASOPRESSIN |
SOLUTION;INTRAVENOUS |
20UNITS/ML (20UNITS/ML) |
Prescription |
No |
No |
AP |
2022/08/15
|
EUGIA PHARMA |
| 213206 |
001 |
ANDA |
VASOPRESSIN |
VASOPRESSIN |
SOLUTION;INTRAVENOUS |
20UNITS/ML (20UNITS/ML) |
Prescription |
No |
No |
AP |
2023/05/26
|
FRESENIUS KABI USA |
| 216963 |
001 |
ANDA |
VASOPRESSIN |
VASOPRESSIN |
SOLUTION;INTRAVENOUS |
20UNITS/ML (20UNITS/ML) |
Prescription |
No |
No |
AP |
2024/02/09
|
GLAND |
| 213988 |
001 |
ANDA |
VASOPRESSIN |
VASOPRESSIN |
SOLUTION;INTRAVENOUS |
20UNITS/ML (20UNITS/ML) |
Prescription |
No |
No |
AP |
2024/05/08
|
DR REDDYS |
>>>活性成分:VASOPRESSIN; 剂型/给药途径:SOLUTION;INTRAVENOUS; 规格:40UNITS/100ML (0.4UNITS/ML); 治疗等效代码:AP<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 204485 |
003 |
NDA |
VASOSTRICT |
VASOPRESSIN |
SOLUTION;INTRAVENOUS |
40UNITS/100ML (0.4UNITS/ML) |
Prescription |
Yes |
Yes |
AP |
2020/04/15
|
PH HEALTH |
| 216963 |
002 |
ANDA |
VASOPRESSIN IN DEXTROSE 5% |
VASOPRESSIN |
SOLUTION;INTRAVENOUS |
40UNITS/100ML (0.4UNITS/ML) |
Prescription |
No |
No |
AP |
2025/08/22
|
GLAND |
>>>活性成分:VASOPRESSIN; 剂型/给药途径:SOLUTION;INTRAVENOUS; 规格:20UNITS/100ML (0.2UNITS/ML); 治疗等效代码:AP<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 204485 |
005 |
NDA |
VASOSTRICT |
VASOPRESSIN |
SOLUTION;INTRAVENOUS |
20UNITS/100ML (0.2UNITS/ML) |
Prescription |
Yes |
Yes |
AP |
2021/04/21
|
PH HEALTH |
| 217987 |
001 |
ANDA |
VASOPRESSIN |
VASOPRESSIN |
SOLUTION;INTRAVENOUS |
20UNITS/100ML (0.2UNITS/ML) |
Prescription |
No |
No |
AP |
2023/12/06
|
CIPLA |